Royalty Report: Drugs, Delivery, Pharmaceuticals – Collection: 1724


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Delivery
  • Pharmaceuticals
  • Personal Care Products
  • Therapeutic
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1724

License Grant
The Company entered into a second exclusive, worldwide, royalty bearing license agreement with the University for two patents, the rights to which are jointly held by the Licensor and Cellegy, for Drug Delivery By Skin Barrier Disruption.
License Property
This technology selectively modulates the skin’s barrier, with the goals of opening the skin barrier wider and keeping it open for a longer period of time (which may allow for the transdermal and topical delivery of larger and/or water soluble therapeutic, nutritional and cosmetic molecules), and reducing the potential for inducing skin inflammation, which sometimes accompanies use of certain traditional drug delivery technologies.
Field of Use
The rights granted apply to skin's barrier.

IPSCIO Record ID: 26398

License Grant
The Company has been granted of exclusive licensing and marketing rights to TheraTech, ownership of patents by the University; drug delivery research and development programs, controlled release drug delivery products which administer drugs through the skin, by oral delivery.

IPSCIO Record ID: 367578

License Grant
Israeli Licensor hereby grants to the Licensee an exclusive worldwide through multiple tier license, in the Territory, to 1) the Intellectual Property Rights resulting from and/or arising under the Development Plan and/or Development Results including Resulting Patents, and/or the Drug Formulation and/or Product ; and 2) to make, have made, use, have used and/or license the Drug Formulation and/or the Development Results, and 3) to make, have made, sell, have sold, use, have used, license, and/or import Product; and 4) an exclusive license in the Territory to any Patents covering the Drug Formulation and Product to enable the Licensee to make, have made, sell, have sold, and/or use Products. The Licensee shall not use the Drug Formulation and/or the Development Results for any purpose other than exercise of the License. Licensor hereby grants to the Licensee a non-exclusive license, in the Territory under the Licensor Patents, to use the Licensor Formulation Technology to 1) develop, make, have made, and use, the Drug Formulation, and 2) develop, make, have made, sell, have sold, and use, Product.
License Property
Licensor Patents shall mean the patents and/or patent applications covering or disclosing Licensor Formulation Technology; and including but not limited to,  U.S. Patent No. 5,540,934, U.S. Patent No. 5,716,638 and PCT International Application No. PCT/EP95/02397 and any continuations, continuations-in-part, extensions, divisions, substitutions or additions to such applications and all patents which are reissues thereof, re-validations and registrations based thereon, and any and all foreign patents and patent applications corresponding thereto.

5,540,934 – Compositions for applying active substances to or through the skin
5,716,638 – Composition for applying active substances to or through the skin

Product means a pharmaceutical preparation or composition containing the Drug Formulation which is covered by a Valid Patent Claim.

Drug means the Licensees organoselenium drug or materials, as specified in this Agreement, and its racemate, metabolite, derivatives, isomers, polymorphs, crystals.

Drug Formulation means the formulation of the Drug utilizing Licensors Formulation Technology.

Field of Use
Field of use is for Ethosome, a non-invasive, transdermal drug delivery technology.

Ethosomes are phospholipid nanovesicles used for dermal and transdermal delivery of molecules.

IPSCIO Record ID: 27978

License Grant
The University grants to Licensee a world-wide license under  the University's Patent Rights to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law.  The University also grants to Licensee the right to issue sublicenses to third parties to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method in the Field of Use as long as Licensee has current exclusive rights thereto under this Agreement.
License Property
Certain inventions, generally characterized as “Lipids for Epidermal Moisturization and Repair of Barrier Function”.

The Licensor for barrier repair technology is a technology that is a specific combination of ceramides, cholesterol and fatty acids which are able to create a human-like skin barrier and thus provide patients with a more normal skin barrier function.

The Barrier Repair platform represents near term revenue opportunities for prescription skin care products to treat a variety of skin disorders all characterized by a disrupted skin barrier.  In April 2006, the licensor received clearance from the United States Food and Drug Administration (FDA) to market EpiCeram® their first commercial product using the Barrier Repair technology.  EpiCeram® is a prescription-only topical cream intended to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses including atopic dermatitis (eczema), irritant contact dermatitis, and radiation dermatitis.

Field of Use
Field of Use means therapeutic and cosmetic applications in mammals, including humans.

IPSCIO Record ID: 26964

License Grant
The Company obtained a non-exclusive license over the HIT Technology to exclusively exploit its anti-cancer HyACT(TM) project worldwide.
License Property
Hyaluronan Induced Targeting (HIT) is topical drug delivery technologies, based on hyaluronan (HA), a natural polymer, which are primarily designed to maintain efficacy and localize delivery of drugs to the skin for the treatment of a variety of skin disorders.
Field of Use
The rights granted apply to skin disorders.

IPSCIO Record ID: 1723

License Grant
The Company entered into a license agreement with the University providing for an exclusive, world-wide, royalty bearing license, subject to customary government rights, for two use patents for Barrier Repair Formulations; technology, that repairing the skin barrier may improve the skin’s ability to protect against environmental and occupational insults and thus may help prevent skin diseases and help alleviate conditions such as photoaging and wrinkling.
Field of Use
The rights granted apply to the skin.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.